Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Beijing Airdoc Technology Co. Ltd. Class H ( (HK:2251) ).
Beijing Airdoc Technology reported revenue of RMB173.3 million for 2025, up from RMB156.4 million a year earlier, driven by growth in its AI-enabled healthcare solutions. The company operates with substantial non-current assets and a solid equity base, reflecting its continued investment in technology and data capabilities to support long-term expansion.
Despite the revenue increase and a sharp improvement in gross profit to RMB128.0 million, the group still recorded a net loss of RMB24.4 million for 2025, although this was significantly narrower than the RMB265.1 million loss in 2024. The reduced losses, lower cost of sales and stable asset position suggest improving operational efficiency and a gradual move toward potential profitability, which may reassure investors about the company’s financial trajectory.
The most recent analyst rating on (HK:2251) stock is a Hold with a HK$11.00 price target. To see the full list of analyst forecasts on Beijing Airdoc Technology Co. Ltd. Class H stock, see the HK:2251 Stock Forecast page.
More about Beijing Airdoc Technology Co. Ltd. Class H
Beijing Airdoc Technology Co., Ltd. is a China-based company listed in Hong Kong that operates in the technology and healthcare-related industries, providing AI-driven diagnostic and health management solutions. The group focuses on leveraging software and data analytics to support medical and health applications, targeting both institutional clients and broader healthcare markets.
Average Trading Volume: 98,581
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.03B
For detailed information about 2251 stock, go to TipRanks’ Stock Analysis page.